Tags : AZD1222

AstraZeneca Expands Supply Agreement with Oxford Biomedica for AZD1222 to

Shots: The companies have signed an 18mos. supply agreement under a 3yrs. master supply and development agreement. Oxford Biomedica to receive $17.95M up front as a capacity reservation fee and expects to receive additional revenue of $41.89M + materials costs for the manufacturing of multiple large-scale batches of AZD1222 until the end of 2021 Oxford […]Read More

AstraZeneca Expands the Development of AZD1222 into P-III Study in

Shots: AstraZeneca has expanded the development of AZD1222 into P-III D8110C00001 study to assess its safety, efficacy, and immunogenicity. BARDA has funded the P-III study to accelerate the development of the vaccine The P-III D8110C00001 study involves assessing of AZD1222 vs PBO for the prevention of COVID-19, in up to 30,000 participants aged ≥ 18yrs. […]Read More

AstraZeneca Signs an Agreement with Emergent BioSolutions to Expand Manufacturing

Shots: Emergent will provide CDMO services for AstraZeneca’ AZD1222. The agreement valued ~174M through 2021 and follows an $87M agreement signed in June for development services, performance and process qualification, raw materials, and an initial capacity reservation The two companies may enter additional commercial manufacturing agreement as the candidate progresses over three years through Emergent’s […]Read More

Daiichi Sankyo in Talks with AstraZeneca for the Supply of

Shots: Following the AstraZeneca’s discussion with the Japanese government to introduce COVID-19 vaccine in Japan, Daiichi Sankyo has advanced its conversation with AstraZeneca to formulate the vaccine, including vial filling, packaging, and storage Daiichi Sankyo plans to receive Oxford’s undiluted vaccine, which it will finish at its own facilities. The collaboration allows AstraZeneca to reach […]Read More

AstraZeneca Signs an Agreement with Symbiosis for Sterile Manufacturing of

Shots: Symbiosis will provide AstraZeneca access to its sterile vaccine drug product manufacturing capacity for clinical trial supply The agreement follows AstraZeneca’s licensing agreement with the University of Oxford for the global development, manufacturing, and distribution of the AZD1222 vaccine candidate. The vaccine candidate is currently in clinical trials at multiple sites in the UK […]Read More

AstraZeneca Signs an Agreement with Catalent to Manufacture AZD1222 for

Shots: Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Italy and prepare for large-scale commercial supply of AZD1222 The agreement ramps up the production of AZD1222 and will prepare the facility to enable round-the-clock manufacturing schedules and supply hundreds of millions of doses of AZD1222 from Aug’2020 […]Read More